In anti-estrogen-responsive breast cancers, tamoxifen causes a reduction in cyclin D1 expression, reducing CDK4/6 activity and promoting p27Kip1/p21Waf1/Cip1 inhibition of CDK2, resulting in decreased pRb phosphorylation and G1 cell cycle arrest (Planas-Silva and Weinberg, 1997). Here, CDK2 is linked to breast cancer.